**Molnupiravir**

**Purpose:** For the treatment of mild to moderate COVID-19, patients must have tested positive for COVID-19 and *are at high risk of progression to hospitalization and/or death* (ie. elderly age, high risk conditions, and/or weakened immune system) and for whom alternative COVID-19 treatment options are not accessible or clinically appropriate. This is *not* for pre or post exposure. Treatment should be initiated within 5 days of symptom onset.

**Age Requirement:** 18 years and older

**Dosing and Administration:** Take four capsules of molnupiravir (200 mg) by mouth every 12 hours for 5 days

**Side Effects:** dizziness,nausea, and diarrhea

**Efficacy:** Adjusted relative risk reduction of molnupiravir compared to placebo for all randomized subjects was 30% (95% CI: 1%, 51%).

| **Clinical Pearls**   * Not recommended for use during pregnancy. Assess whether patients with child-bearing are pregnant before initiation of therapy.   + **Females:** Reliable form of birth control should be used during treatment *AND* four days after final dose   + **Males:** Should use reliable form of contraception during treatment *AND* **three months** after final dose * Breastfeeding: Pump and dump during treatment and 4 days after last dose * Renal dose adjustments: No dosage adjustment in patients with any degree of renal impairment is recommended. * Hepatic dose adjustments: No dosage adjustment is recommended. * Do not chew, crush, or break capsules * Instruct patients that if they miss a dose of molnupiravir and it is within 10 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. Advise the patient to not double the dose to make up for a missed dose. |
| --- |

At this point in time, supply is extremely limited, so prescriptions for oral COVID-19 treatment will not be filled until we speak to the patient/caregiver to confirm eligibility. Patients will be called in the order in which prescriptions are received and oral therapeutics will be filled in the order in which we speak to patients. All patients will be provided with a copy of the Patient EUA Fact Sheet, and every course will be tagged “Do not dispense after XX date” to prevent dispensing outside of the 5-day treatment window. We will enforce **contactless** dispensing of COVID therapeutics, so please ask your patients to remain outside of the pharmacy and to call us if they have any questions.

Thank you for your partnership with Moose Pharmacy!

Please call us with any questions and feel free to fax prescriptions using the provided template on the next page.

**P:** (704) 436-9613  **F:** (704)436-6512